Overview

High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of high-dose combination chemotherapy followed by peripheral stem cell transplantation in treating patients with lung cancer.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Herbert Irving Comprehensive Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Etoposide
Etoposide phosphate
Ifosfamide
Isophosphamide mustard
Paclitaxel
Criteria
DISEASE CHARACTERISTICS: Histologically or cytologically diagnosed lung cancer including
the following: Relapsed limited stage small cell lung cancer (SCLC) Limited stage SCLC
responding to conventional radiotherapy Extensive stage SCLC Stage IIIB and IV non-small
cell lung cancer (NSCLC) Stages II-IIIA NSCLC who are unable or unwilling to undergo
surgery but are acceptable candidates for high dose chemotherapy Cryopreserved peripheral
blood stem cells with CD34 count greater than 2000/mm3 No untreated or uncontrolled brain
metastases

PATIENT CHARACTERISTICS: Age: Any age Performance status: Karnofsky 60-100% Life
expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin less than 1.5
times normal SGOT less than 1.5 times normal Renal: Creatinine clearance greater than 50
mL/min Pulmonary: Left ventricular ejection fraction greater than 45% DLCO greater than 40%
Other: Not pregnant or lactating No medical or psychiatric illness preventing informed
consent or intensive treatment

PRIOR CONCURRENT THERAPY: Concurrent chemotherapy allowed if no evidence of disease
progression